You are here

Article Text

Article menu

Download PDFPDF

Abstracts of Poster and e-Poster Presentations
PA-539 Developing hands-on skills on tuberculosis sponsor responsibilities and clinical trial management for END-TB in Sub-Saharan
Free
  1. Alphonce Liyoyo1,
  2. Hamu Mlyuka2,
  3. Iris Spelier3,
  4. Jodie Schildkraut3,
  5. Julie Anderson4,
  6. Hadija Semvua5,
  7. Oscar Kaswaga1,
  8. Marion Sumari-de-Boer5,
  9. Leticia Wildner6,
  10. Wilber Sabiiti4,
  11. Tim McHugh6,
  12. Emmanuel Mpolya7,
  13. Bayodé Adegbite8,
  14. Mariott Nliwasa9,
  15. Celco Khosa10,
  16. Peter Mbelele1,
  17. Martin Boeree3,
  18. Leandra Leombard11,
  19. Stephen Gillespie4,
  20. Derek Sloan4,
  21. Stellah Mpagama1
  1. 1Kibong’oto Infectious Diseases Hospital, Tanzania
  2. 2Muhimbili University College of Health and Allied Sciences, Tanzania
  3. 3Radboudumc Centre for Infectious Diseases, Dept of Pulmonary Diseases, Radboud University Medical Center, The Netherlands
  4. 4School of Medicine, University of St Andrews UK
  5. 5Kilimanjaro Christian Medical Centre, Tanzania
  6. 6Centre for Clinical Microbiology, University College London, UK
  7. 7Department of Global Health and Biomedical Sciences, Nelson Mandela African Institution of Science and Technology, Tanzania
  8. 8Centre de Recherches Médicales de Lambaréné, Gabon
  9. 9Kamuzu College of Health Sciences, Malawi
  10. 10Instituto Nacional de Saúde, Bairro da vila – parcela, Mozambique
  11. 11TB Alliance, South Africa

Abstract

Background The END TB strategy recommends scaling up of research training and capacity by growing the workforce of scientists in tuberculosis (TB) endemic settings skilled in “development and rapid uptake of new TB tools and “interventions” and “research to optimise implementation and impact”. The SimpliciTB consortium aimed to develop the skills, confidence and international competitiveness of African research leaders engaging in TB while extending network of African sites capable of performing high quality clinical trials in TB.

Methods Through co-leadership and partnership with St Andrews University, University College London from United Kingdom; Radboud University Medical Center-The Netherlands and TB Alliance-United States mentorship was provided to the senior clinical research fellow and clinical research & development fellow based at Kibong’oto Infectious Diseases Hospital in Tanzania to execute sponsor and trial management responsibilities for a new clinical trial of anti-TB therapy to be delivered in four African countries: Gabon, Malawi, Mozambique and Tanzania.

Results From January 2022- April 2023, achievement in capacity development include design of the potential regimen for a phase III TB clinical trial, and development of the protocol titled: “A pragmatic trial with optimized dose of rifampicin and moxifloxacin for the treatment of drug susceptible pulmonary tuberculosis (OptiRiMoxTB)”. The Operational team meeting was successfully formulated comprising of two categories i) sponsor category with international principal investigators as co-chairs, trial manager and associated core groups including biostatistics and data management, pharmacy and drug management, microbiology and biomarkers, finance and administration and ii) Trial sites each bringing at least the site PI, and site coordinators. Trial-governance including the data safety monitoring and steering committees are set. All sites have submitted ethical and regulatory clearance to their respective bodies and authorities.

Conclusion Despite challenges, the preparatory phase has completed and enrolment of participants expects to start in the second quarter of 2023.

https://doi.org/10.1136/bmjgh-2023-EDC.232

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.